These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 39075994)

  • 1. [Long-term health-related quality of life and related factors in children with severe hemophilia A who received regular low-dose prophylaxiss].
    Li Z; Zhou Y; Zhang SN; Li KX; Zhao YQ; Wang SJ; Xiao J
    Zhonghua Yi Xue Za Zhi; 2024 Jul; 104(29):2745-2750. PubMed ID: 39075994
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term joint outcomes of regular low-dose prophylaxis in Chinese children with severe haemophilia A.
    Wu Y; Lu J; Zhou Y; Li K; Liu Y; Liu S; Li Z; Zhao Y; Poon MC; Xiao J
    Haemophilia; 2021 Mar; 27(2):237-244. PubMed ID: 33550696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes of low-dose pharmacokinetic-guided extended half-life versus low-dose standard half-life factor VIII concentrate prophylaxis in haemophilia A patients.
    Rakmanotham A; Moonla C; Sosothikul D
    Haemophilia; 2023 Jan; 29(1):156-164. PubMed ID: 36409282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twice Weekly Vs. Thrice Weekly Low-Dose Prophylactic Factor VIII Therapy in Children with Hemophilia A: An Open Label Randomized Trial.
    Gomber S; Singhal G; Dewan P; Upreti L; Sikka M
    J Trop Pediatr; 2022 Apr; 68(3):. PubMed ID: 35595254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hemophilia-Specific Quality of Life Index (Haemo-QoL and Haem-A-QoL questionnaires) of children and adults: result of a single center from Turkey.
    Mercan A; Sarper N; Inanir M; Mercan HI; Zengin E; Kiliç SÇ; Gökalp AS
    Pediatr Hematol Oncol; 2010 Sep; 27(6):449-61. PubMed ID: 20615067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moderate- to vigorous-intensity physical activities for hemophilia A patients during low-dose pharmacokinetic-guided extended half-life factor VIII prophylaxis.
    Srichumpuang C; Rakmanotham A; Moonla C; Sosothikul D
    Orphanet J Rare Dis; 2024 Mar; 19(1):135. PubMed ID: 38532451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life and health status in adolescent and adult people with haemophilia A without factor VIII inhibitors-A non-interventional study.
    Oldenburg J; Tran H; Peyvandi F; Núñez R; Trask P; Chebon S; Mahlangu JN; Lehle M; Jiménez-Yuste V; von Mackensen S
    Haemophilia; 2021 May; 27(3):398-407. PubMed ID: 33576546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.
    Olasupo OO; Noronha N; Lowe MS; Ansel D; Bhatt M; Matino D
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD014544. PubMed ID: 38411279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa.
    Santagostino E; Lentz SR; Busk AK; Regnault A; Iorio A
    Haemophilia; 2014 Jul; 20(4):527-34. PubMed ID: 24471912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Study of physical function in adolescents with haemophilia: The SO-FIT study.
    Khair K; Holland M; Bladen M; Griffioen A; McLaughlin P; von Mackensen S;
    Haemophilia; 2017 Nov; 23(6):918-925. PubMed ID: 28806864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the impact of hemophilia: the Academic Achievement in Children with Hemophilia Study.
    Shapiro AD; Donfield SM; Lynn HS; Cool VA; Stehbens JA; Hunsberger SL; Tonetta S; Gomperts ED;
    Pediatrics; 2001 Dec; 108(6):E105. PubMed ID: 11731632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prophylactic treatment with low- and intermediate-dose factor VIII in children with severe hemophilia A: comprehensive evaluation of joint outcomes and correlation analysis].
    Zhuang JM; Sun XY; Zhou X; Liu ZQ; Sun J
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Apr; 38(4):496-501. PubMed ID: 29735454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Analysis of the effects of low/intermediate dose of coagulation factor Ⅷ on 30 adult patients with severe hemophilia A in a single center].
    Yuan YH; Xu PP; Xu YY; Liu S; Shao XY; Zhang WJ; Gong L; Zhou M; Chen B; Zhou RF
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jan; 44(1):38-42. PubMed ID: 36987721
    [No Abstract]   [Full Text] [Related]  

  • 14. Prophylaxis with anti-inhibitor coagulant complex improves health-related quality of life in haemophilia patients with inhibitors: results from FEIBA NF Prophylaxis Study.
    Stasyshyn O; Antunes S; Mamonov V; Ye X; Epstein J; Xiong Y; Tangada S
    Haemophilia; 2014 Sep; 20(5):644-50. PubMed ID: 24589084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study.
    Li C; Zhang X; Zhao Y; Wu R; Hu Q; Xu W; Sun J; Yang R; Li X; Zhou R; Lian S; Gu J; Wu J; Hou Q
    Curr Med Res Opin; 2017 Jul; 33(7):1223-1230. PubMed ID: 28326849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of late prophylaxis in hemophilia on joint status: a randomized trial.
    Manco-Johnson MJ; Lundin B; Funk S; Peterfy C; Raunig D; Werk M; Kempton CL; Reding MT; Goranov S; Gercheva L; Rusen L; Uscatescu V; Pierdominici M; Engelen S; Pocoski J; Walker D; Hong W
    J Thromb Haemost; 2017 Nov; 15(11):2115-2124. PubMed ID: 28836341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Efficacy of short-term full-dose prophylaxis in adult Chinese patients with severe hemophilia A].
    Sun X; Zhuang J; Zhou X; Li H; Liu Z; Sun J
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Sep; 38(10):1222-1227. PubMed ID: 30377129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in health-related quality of life with treatment of longer-acting clotting factors: results in the A-LONG and B-LONG clinical studies.
    Wyrwich KW; Krishnan S; Auguste P; Poon JL; von Maltzahn R; Yu R; Pierce GF; Mei B; Mahlangu J; von Mackensen S
    Haemophilia; 2016 Nov; 22(6):866-872. PubMed ID: 27385432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of standard prophylaxis versus on-demand treatment with bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A.
    Zhao Y; Xiao J; Yang R; Wu R; Hu Y; Beckmann H; Wu J; Hou Q; Sun J
    Pediatr Hematol Oncol; 2017 Apr; 34(3):138-148. PubMed ID: 28727494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of FVIII doses on joint structure and function in adolescents with severe hemophilia A: mid-term results of a prospective cohort study].
    Meng L; Zhuang J; Sun X; Liu Z; Zhou X; Liu H; Zhou F; Li Y; Sun J
    Nan Fang Yi Ke Da Xue Xue Bao; 2021 Apr; 41(4):536-542. PubMed ID: 33963712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.